Introduction

Breast cancer is the most common female  cancer worldwide  representing nearly a quarter (25%) of all cancers. In India although age adjusted incident rate of breast cancer is lower (25.8 per 100000) than U.K(95 per 100000) but mortality is at par(12.7 vs 17.1 per 100000) with U.K. There is significant increase incidence and cancer associated morbidity & mortality in Indian subcontinent. The age adjusted Incidence rate of  Carcinoma of breast was found as high as 41 per 100000 women for Delhi , followed by Chennai (37.9), Bangalore (34.4) & Thiruvananthapuram  district (33.7).¹

1. Shreshthamalva, et al. Epidemology of breast cancer in Indian women. Ascian-pacific journal of clinical oncology 2017,13,289-295.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015
3. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018
4. john Hopkins medicine and pathology, types of breast cancer.
5. New ASCO guidelines call for determining HER2 status of every invasive breast cancer, 23-oct-2013.
6. Sternberg, Stephen S., Stacey E Mills, and Darryl Carter. Sternberg's Diagnostic SurgicalPathology. 6th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2015
7. Adidayo A .onitilo, MD, MSCR, FACP, etal .Breast cancer subtypes based on ER/PR and HER2 expression, comparision of clinicopathological features and survival-2008 clinical medicine and research -13 ,volume 7, number ½,4 .
8. Murtuzarampurwala, et al. role of androgen receptor in triple negative breast cancer, clinical advances in haematology and oncology march 2016 volume 14, issue 3.
9. mishra, et al. Expression of androgen receptor in breast carcinoma and its correlation with other steroid receptors and growth factors.Inj J med Res 135 june 2012 pp 843-852.
10. Zhuang Y, Saaristo R, Ylikomi T: An in vitro longterm culture model for normal human mammary gland: expression and regulation of steroid receptors. Cell Tissue Res 2003;311:217–226
11. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH: Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991;39:927–936.
12. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H: Immunocytochemical localization of androgen receptor with polyclonalantibody in paraffin-embedded human tissues. J Histochem Cytochem 1993;41:671–678.
13. Janssen PJ, Brinkmann AO, Boersma WJ, Van der Kwast TH: Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem 1994;42:1169–1175.
14. Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD: Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 2007;21: 2285–2293. 36 Riva C, Dainese E, Caprara G, Rocca PC, Massarel
15. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA: Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14: 1725–1730.
16. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10: 292–298.
17. Jayo MJ, Register TC, Hughes CL, Blas-Machado U, Sulistiawati E, Borgerink H, Johnson CS: Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig 2000;7:257–265.
18. Somboonporn W, Davis SR: Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004;25:374–388.
19. Lapointe J, Fournier A, Richard V, Labrie C: Androgens down-regulate bcl-2 protooncogene expression in ZR-75–1 human breast cancer cells. Endocrinology 1999;140:416–421.
20. Hatzoglou A, Kampa M, Kogia C, Charalampopoulos I, Theodoropoulos PA, Anezinis P, Dambaki C, Papakonstanti EA, Stathopoulos EN, Stournaras C, Gravanis A, Castanas E: Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab 2005;90:893–903.
21. Yeh S, Hu Y, Wang P, Xie C, Xu Q, Tsai M, Dong Z, Wang R, Lee T and Chang C: Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 198: 1899-1908, 2003
22. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767, 2011.
23. Chia KM, Liu J, Francis GD and Naderi A: A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13: 154-166, 2011.
24. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG and Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 30: 3019-3027, 2011.
25. Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, Song YJ, Zan LK, Zhang X, Zhou M, et al: Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl) 6: 1-8, 2012.
26. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
27. Choi JE, Kang SH, Lee SJ and Bae YK: Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22: 82-89, 2015.
28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138: 241-256, 2014.
29. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: e48-e72, 2010.
30. Lehmann BD and Pietenpol JA: Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232: 142-150, 2014.
31. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C and Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008, 2006.
32. Tsutsumi Y: Apocrine carcinoma as triple-negative breast cancer: Novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol 42: 375-386, 2012.
33. Xu H, Eirew P, Mullaly SC and Aparicio S: The omics of triple-negative breast cancers. ClinChem 60: 122-133, 2014.
34. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018
35. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H and Kantoff PW: Current treatment strategies for advanced prostate cancer. Int J Urol, 2017.
36. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J ClinOncol 25: 1596-1605, 2007.
37. Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A and Ocana A: Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 14: 302, 2014.
38. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al: Phase II Trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 19: 5505-5512, 2013.
39. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, et al: Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J ClinOncol: JCO2016713495, 2018.
40. Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS and Dalton JT: Selective Androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial: Mesenchymal stem cell signaling. PLoS One 9: e103202, 2014
41. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, et al: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 16: 406, 2014
42. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer.Cancer. 2007;109(1):25-32.
43. Sutton LM, Cao D, Sarode V, et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J ClinPathol. 2012;138(4):511-516.
44. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29(6):585-590.
45. Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.
46. Clinical Trials.gov. Taselisib and enzalutamide in treating patients with androgen receptor positive triple-negative metastatic breast cancer. https:// clinicaltrials.gov/ct2/results?term=NCT02457910&Search=Search. Identifier: NCT02457910. Accessed January 29, 2016.
47. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130-146.
48. Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 1995;90(1):43-50.
49. Dukelow T, Kishan D, Khasraw M, Murphy CG.CDK4/6 inhibitors in breast cancer. Anticancer Drugs. 2015;26(8):797-806.
50. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
51. Turner NC, Ro J, André F, et al; PALOMA3 Study Group. Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-219.
52. Asghar U, Herrera-Abreu MT, Cutts R, et al. Identification of subtypes of triple negative breast cancer (TNBC) thatare sensitive to CDK4/6 inhibition [ASCO abstract 11098]. J Clin Oncol. 2015;33(15)(suppl).

Dr M.Srividya DNB Pathology